Viking secures 1b supply of obesity pill candidate with $150m prepayment deal

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.

Viking Therapeutics is putting $150 million down to secure future supply of “multiple metric tons” of its investigational obesity medication VK2735. The deal will set up an annual capacity of more than 1 billion pills, 100 million autoinjectors and 100 million vial and syringe products.